Michael E. Perlman, PhD

Associate Scientific Fellow, Drug Product Development and Devices/Analytical Development
Takeda Pharmaceutical Company Limited

Poster(s):

• (W1130-02-13) Multi-Compartment In Vitro Dissolution Testing to Study the Potential Impact of API Changes on Drug-in-Capsule Absorption for Mobocertinib, a Weak Base with Complex pH-Dependent Solubility
  Wednesday, November 12, 2025

  11:30 AM - 12:30 PM CT

• (M1230-05-31) Physiologically Based Biopharmaceutics Modeling of Formulation Bioequivalence for Mobocertinib, a Weak Base, Using pH-Dependent Dissolution Data
  Monday, November 10, 2025

  12:30 PM - 1:30 PM CT